scholarly journals CCAAT/enhancer-binding protein beta (C/EBPβ) is an important mediator of 1,25 dihydroxyvitamin D3 (1,25D3)-induced receptor activator of nuclear factor kappa-B ligand (RANKL) expression in osteoblasts

BMB Reports ◽  
2019 ◽  
Vol 52 (6) ◽  
pp. 391-396 ◽  
Author(s):  
Sungsin Jo ◽  
Yun Young Lee ◽  
Jinil Han ◽  
Young Lim Lee ◽  
Subin Yoon ◽  
...  
Keyword(s):  
Nuclear Factor Kappa B ◽  
Binding Protein ◽  
Nuclear Factor ◽  
Rankl Expression ◽  
Dihydroxyvitamin D3 ◽  
1,25 Dihydroxyvitamin D3 ◽  
Nuclear Factor Kappa ◽  
Important Mediator ◽  
Enhancer Binding Protein ◽  
Receptor Activator

scholarly journals 1,25-Dihydroxyvitamin D3 Inhibits the RANKL Pathway and Impacts on the Production of Pathway-Associated Cytokines in Early Rheumatoid Arthritis

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Jing Luo ◽  
Hongyan Wen ◽  
Hui Guo ◽  
Qi Cai ◽  
Shuangtian Li ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Signaling Pathway ◽  
Nuclear Factor Kappa B ◽  
Mononuclear Cells ◽  
Enzyme Linked Immunosorbent Assay ◽  
Nuclear Factor ◽  
Peripheral Blood Mononuclear ◽  
Dihydroxyvitamin D3 ◽  
1,25 Dihydroxyvitamin D3 ◽  
Receptor Activator

Objectives. To study effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on RANKL signaling pathway and pathway-associated cytokines in patients with rheumatoid arthritis (RA).Methods. Receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin (OPG), IFN-γ, IL-6, TNF-α, IL-17, and IL-4 were examined in 54 patients with incipient RA using a cytometric bead array (CBA) or an enzyme-linked immunosorbent assay (ELISA).Results. After 72 hours of incubation of peripheral blood mononuclear cells (PBMCs) with 1,25(OH)2D3in RA patients, the levels of RANKL, TNF-α, IL-17 and IL-6 significantly decreased compared to those of the control. 1,25(OH)2D3had no significantly impact on the levels of OPG, RANKL/OPG, and IL-4.Conclusions. The present study demonstrated that 1,25(OH)2D3reduced the production of RANKL and the secretion of TNF-α, IL-17, and IL-6 in PBMCs of RA patients, which indicated that 1,25(OH)2D3might be able to decrease damage of cartilage and bone in RA patients by regulating the expression of RANKL signaling pathway and pathway-associated cytokines.

scholarly journals Triiodothyronine (T3) does not induce Rankl expression in rat Ros 17/2.8 cells

2008 ◽  
Vol 52 (1) ◽  
pp. 109-113 ◽  
Author(s):  
Patrícia P. Saraiva ◽  
Silvania S. Teixeira ◽  
Célia Regina Nogueira ◽  
Carlos Roberto Padovani
Keyword(s):  
Messenger Rna ◽  
Nuclear Factor Kappa B ◽  
Osteoclast Differentiation ◽  
Hormone Treatment ◽  
Nuclear Factor ◽  
Rankl Expression ◽  
Loss Mechanism ◽  
Nuclear Factor Kappa ◽  
Rankl Mrna ◽  
Receptor Activator

Osteoclastogenesis may be regulated via activation of the RANK/RANKL (receptor activator of nuclear factor-kappa B/ receptor activator of nuclear factor-kappa B ligand) system, which is mediated by osteoblasts. However, the bone loss mechanism induced by T3 (triiodothyronine) is still controversial. In this study, osteoblastic lineage rat cells (ROS 17/2.8) were treated with T3 (10-8 M, 10-9 M, and 10-10 M), and RANKL mRNA (messenger RNA) expression was measured by semiquantitative RT-PCR. Our results show that T3 concentrations used did not significantly enhance RANKL expression compared to controls without hormone treatment. This data suggests that other mechanisms, unrelated to the RANK/RANKL system, might be to activate osteoclast differentiation in these cells.

scholarly journals Evaluation of the Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Expression in Osteosarcoma and Its Association with the Clinicopathological Data

2021 ◽  
Vol 22 (3) ◽  
pp. 741-747
Author(s):  
Hui Chua ◽  
Sharifah Emilia Tuan Sharif ◽  
Wan Faisham Nu’man Wan Ismail ◽  
Muhamad Syahrul Fitri Zawawi ◽  
Sarimah Abdullah
Keyword(s):  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
Rankl Expression ◽  
Nuclear Factor Kappa ◽  
Receptor Activator
Sign in / Sign up

Export Citation Format

Share Document